[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011093812A3 - Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form - Google Patents

Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form Download PDF

Info

Publication number
WO2011093812A3
WO2011093812A3 PCT/TR2011/000014 TR2011000014W WO2011093812A3 WO 2011093812 A3 WO2011093812 A3 WO 2011093812A3 TR 2011000014 W TR2011000014 W TR 2011000014W WO 2011093812 A3 WO2011093812 A3 WO 2011093812A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
budesonide
dry powder
powder form
pharmaceutical formulation
Prior art date
Application number
PCT/TR2011/000014
Other languages
French (fr)
Other versions
WO2011093812A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00621A external-priority patent/TR201000621A2/en
Priority claimed from TR2010/00732A external-priority patent/TR201000732A2/en
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093812A2 publication Critical patent/WO2011093812A2/en
Publication of WO2011093812A3 publication Critical patent/WO2011093812A3/en
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/19—Constructional features of carpules, syringes or blisters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions in dry powder form comprising tiotropium and budesonide and/or their pharmaceutically acceptable derivatives as active agents, and capsule and blister forms containing these pharmaceutical compositions so as to be used in the treatment of respiratory tract diseases.
PCT/TR2011/000014 2009-12-25 2011-01-28 Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form WO2011093812A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00621A TR201000621A2 (en) 2010-01-28 2010-01-28 Pharmaceutical composition in dry powder form containing tiotropium and budesonide
TR2010/00621 2010-01-28
TR2010/00732 2010-02-02
TR2010/00732A TR201000732A2 (en) 2010-02-02 2010-02-02 Pharmaceutical composition in dry powder form containing tiotropium and budesonide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000015 Continuation-In-Part WO2011093813A1 (en) 2009-12-25 2011-01-28 Dry powder pharmaceutical composition comprising tiotropium and fluticasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 Continuation-In-Part WO2011093810A2 (en) 2009-12-25 2011-01-28 Dry powder pharmaceutical composition comprising tiotropium and mometasone

Publications (2)

Publication Number Publication Date
WO2011093812A2 WO2011093812A2 (en) 2011-08-04
WO2011093812A3 true WO2011093812A3 (en) 2012-02-02

Family

ID=44065663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000014 WO2011093812A2 (en) 2009-12-25 2011-01-28 Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form

Country Status (1)

Country Link
WO (1) WO2011093812A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109220A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium, formoterol and budesonide
WO2013109214A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053648A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Pre-metered dry powder inhaler for moisture-sensitive medicaments
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2005053648A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Pre-metered dry powder inhaler for moisture-sensitive medicaments
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEAT THENG CHOW ET AL: "Investigation of Electrostatic Behavior of a Lactose Carrier for Dry Powder Inhalers", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 25, no. 12, 26 June 2008 (2008-06-26), pages 2822 - 2834, XP019647910, ISSN: 1573-904X, DOI: 10.1007/S11095-008-9651-Y *

Also Published As

Publication number Publication date
WO2011093812A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
IL223795A (en) Tetrahydro-pyrido-pyrimidine derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
IL213019A (en) 1-aza-3-heteroaryl-azulene derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2012021715A3 (en) Stable formulations of linaclotide
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2013114371A8 (en) Dry powder formulations of dnase i
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
TR201000681A2 (en) Dry powder formulations inhaled.
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide
WO2012030308A3 (en) Formulation comprising cellobiose
WO2011037549A3 (en) Dry powder formulation of tiotropium carried in blister strip

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11710053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11710053

Country of ref document: EP

Kind code of ref document: A2